2021 Child Asthma Data: Prevalence Tables

Print
Related Pages
Table C3
Childa Current Asthmab Prevalence
and Weighted Numberc by Age and State or Territory: BRFSS 2021
State Age Group Sample Sized Prevalence (Percent) Standard Error 95% CIe (Percent) || Weighted Numberc 95% CIe Weighted Number
Totalf 0-4 10,623 3.5 0.46 (2.7–4.5) || 463,454 (342,434–584,475)
Totalf 5-9 12,100 6.1 0.42 (5.3–7.0) || 816,328 (703,958–928,698)
Totalf 10-14 18,185 8.0 0.49 (7.1–9.0) || 1,073,842 (944,507–1,203,176)
Totalf 15-17 11,998 9.6 0.68 (8.3–11.0) || 807,989 (689,463–926,515)
AL 0-4 167 5.3 2.04 (2.5–11.1) || 15,350 (3,738–26,963)
AL 5-9 216 10.3 2.89 (5.9–17.5) || 30,138 (12,733–47,542)
AL 10-14 297 10.3 3.11 (5.6–18.2) || 29,720 (10,804–48,636)
AL 15-17 206 14.1 2.87 (9.3–20.7) || 26,236 (15,200–37,271)
CA 0-4 378 4.4 1.45 (2.3–8.3) || 99,578 (33,462–165,693)
CA 5-9 414 3.1 0.81 (1.8–5.1) || 70,700 (34,225–107,176)
CA 10-14 357 5.0 1.51 (2.7–8.9) || 124,214 (50,265–198,164)
CA 15-17 282 8.8 2.56 (4.9–15.3) || 134,928 (53,368–216,489)
CT 0-4 308 5.9 2.47 (2.6–13.1) || 10,459 (1,557–19,361)
CT 5-9 410 7.0 1.91 (4.0–11.8) || 12,889 (5,761–20,017)
CT 10-14 642 10.2 1.72 (7.3–14.1) || 19,696 (12,967–26,426)
CT 15-17 394 13.8 3.28 (8.5–21.5) || 18,129 (8,752–27,505)
DC 0-4 179 6.9 3.21 (2.7–16.5) || 2,728 (110–5,346)
DC 5-9 116 10.1 3.67 (4.8–19.8) || 3,994 (1,033–6,956)
DC 10-14 104 11.1 3.74 (5.6–20.8) || 2,767 (873–4,662)
DC 15-17 79 12.2 4.72 (5.6–24.8) || 2,775 (571–4,980)
GA 0-4 252 4.1 2.19 (1.4–11.3) || 25,349 (0–52,685)
GA 5-9 297 10.3 3.01 (5.7–17.9) || 67,561 (26,212–108,910)
GA 10-14 444 10.1 2.09 (6.7–15.0) || 65,553 (37,807–93,298)
GA 15-17 324 16.5 3.70 (10.5–25.1) || 68,849 (35,176–102,521)
HI 0-4 301 3.6 1.78 (1.4–9.3) || 3,105 (39–6,171)
HI 5-9 336 5.0 2.46 (1.8–12.7) || 4,337 (9–8,664)
HI 10-14 616 5.4 1.35 (3.3–8.7) || 4,364 (2,204–6,524)
HI 15-17 296 7.7 2.66 (3.9–14.8) || 3,712 (1,141–6,283)
IL 0-4 84 (.–.) || 39,386 (.–.)
IL 5-9 107 6.7 2.74 (3.0–14.5) || 49,984 (9,735–90,234)
IL 10-14 211 7.3 2.08 (4.2–12.6) || 49,292 (21,375–77,209)
IL 15-17 97 10.7 4.22 (4.8–22.2) || 39,257 (7,357–71,157)
IN 0-4 409 5.6 1.39 (3.4–9.0) || 22,432 (11,197–33,668)
IN 5-9 387 5.2 1.40 (3.0–8.7) || 21,277 (9,693–32,861)
IN 10-14 740 8.7 1.56 (6.1–12.3) || 35,210 (22,247–48,173)
IN 15-17 407 9.6 1.82 (6.6–13.8) || 25,473 (15,797–35,150)
KS 0-4 832 2.4 0.56 (1.5–3.8) || 4,344 (2,318–6,370)
KS 5-9 1,017 6.6 0.95 (5.0–8.7) || 12,133 (8,630–15,637)
KS 10-14 1,454 10.0 1.05 (8.1–12.3) || 18,212 (14,397–22,027)
KS 15-17 852 12.5 1.58 (9.7–15.9) || 14,748 (10,861–18,635)
KY 0-4 187 (.–.) || 4,120 (.–.)
KY 5-9 238 3.2 1.14 (1.6–6.4) || 8,251 (2,622–13,881)
KY 10-14 329 7.2 1.90 (4.2–11.9) || 17,529 (8,248–26,810)
KY 15-17 228 10.6 2.91 (6.1–17.8) || 17,067 (7,436–26,698)
ME 0-4 343 (.–.) || 353 (.–.)
ME 5-9 399 8.6 1.88 (5.6–13.1) || 5,283 (2,955–7,611)
ME 10-14 568 10.6 2.43 (6.7–16.4) || 6,408 (3,368–9,449)
ME 15-17 406 9.5 1.81 (6.5–13.7) || 3,883 (2,434–5,332)
MD 0-4 581 2.7 0.89 (1.4–5.1) || 9,737 (3,391–16,082)
MD 5-9 635 6.8 1.50 (4.4–10.4) || 24,795 (13,703–35,888)
MD 10-14 1,185 7.7 1.09 (5.8–10.1) || 27,414 (19,614–35,215)
MD 15-17 723 12.1 2.00 (8.7–16.6) || 26,684 (17,563–35,806)
MA 0-4 248 2.8 1.23 (1.2–6.5) || 9,193 (1,292–17,095)
MA 5-9 369 8.9 1.94 (5.8–13.5) || 28,662 (16,119–41,206)
MA 10-14 426 14.6 2.37 (10.5–19.9) || 49,900 (32,800–67,000)
MA 15-17 310 13.5 2.81 (8.8–20.0) || 29,369 (16,584–42,155)
MI 0-4 282 (.–.) || 8,672 (.–.)
MI 5-9 379 7.2 1.83 (4.4–11.7) || 39,545 (19,323–59,767)
MI 10-14 518 8.5 1.90 (5.4–13.0) || 46,738 (25,354–68,122)
MI 15-17 404 12.9 2.36 (9.0–18.3) || 46,675 (28,677–64,673)
MN 0-4 552 1.7 0.87 (0.6–4.6) || 5,901 (0–12,015)
MN 5-9 665 5.7 1.09 (3.9–8.3) || 20,375 (12,633–28,116)
MN 10-14 1,296 6.7 0.86 (5.2–8.6) || 22,813 (17,024–28,603)
MN 15-17 750 11.8 2.05 (8.3–16.4) || 25,944 (16,310–35,577)
MS 0-4 259 4.9 2.14 (2.1–11.3) || 8,663 (1,080–16,245)
MS 5-9 231 12.1 3.21 (7.1–19.9) || 20,035 (8,813–31,257)
MS 10-14 297 14.7 2.68 (10.2–20.8) || 28,384 (17,614–39,154)
MS 15-17 173 7.2 2.10 (4.1–12.6) || 7,918 (3,378–12,458)
MO 0-4 634 4.3 1.23 (2.4–7.5) || 15,420 (6,621–24,218)
MO 5-9 624 5.5 1.35 (3.4–8.8) || 18,493 (9,434–27,551)
MO 10-14 727 10.4 1.87 (7.3–14.7) || 37,083 (23,512–50,653)
MO 15-17 587 8.8 2.24 (5.3–14.3) || 20,035 (9,531–30,539)
MT 0-4 235 3.1 1.17 (1.4–6.4) || 1,896 (470–3,323)
MT 5-9 345 2.6 0.80 (1.4–4.7) || 1,531 (603–2,459)
MT 10-14 412 6.1 1.53 (3.7–9.9) || 3,685 (1,844–5,525)
MT 15-17 264 10.4 2.52 (6.4–16.5) || 3,805 (1,897–5,714)
NE 0-4 689 1.4 0.58 (0.6–3.1) || 1,856 (347–3,365)
NE 5-9 741 6.9 1.71 (4.2–11.1) || 8,894 (4,354–13,434)
NE 10-14 966 7.2 1.25 (5.1–10.0) || 9,221 (5,986–12,457)
NE 15-17 773 8.3 1.52 (5.8–11.8) || 6,542 (4,155–8,929)
NH 0-4 119 (.–.) || 1,581 (.–.)
NH 5-9 148 8.8 2.45 (5.0–14.9) || 5,864 (2,600–9,129)
NH 10-14 287 7.2 1.69 (4.5–11.3) || 4,714 (2,497–6,930)
NH 15-17 275 12.9 3.20 (7.8–20.6) || 5,820 (2,745–8,895)
NJ 0-4 363 2.2 0.89 (1.0–4.8) || 10,824 (2,089–19,559)
NJ 5-9 432 5.6 1.53 (3.3–9.5) || 27,671 (12,560–42,782)
NJ 10-14 524 7.5 1.83 (4.6–12.0) || 39,012 (19,705–58,318)
NJ 15-17 309 6.5 1.97 (3.5–11.6) || 22,199 (8,651–35,746)
NM 0-4 271 2.0 1.47 (0.5–8.1) || 2,474 (0–6,042)
NM 5-9 319 5.8 1.62 (3.3–9.9) || 7,160 (3,185–11,135)
NM 10-14 541 8.3 1.60 (5.7–12.1) || 10,318 (6,388–14,249)
NM 15-17 274 10.2 2.58 (6.2–16.5) || 8,559 (4,163–12,954)
NY 0-4 517 2.9 0.99 (1.5–5.6) || 29,985 (10,313–49,656)
NY 5-9 522 4.9 1.38 (2.8–8.5) || 54,288 (24,003–84,573)
NY 10-14 658 7.9 1.55 (5.4–11.5) || 88,412 (54,260–122,565)
NY 15-17 465 12.3 3.15 (7.3–19.9) || 83,358 (38,134–128,583)
OH 0-4 407 3.5 1.50 (1.5–8.0) || 24,248 (3,748–44,748)
OH 5-9 472 4.6 1.16 (2.8–7.5) || 31,916 (16,257–47,576)
OH 10-14 886 7.4 1.31 (5.2–10.4) || 50,100 (32,185–68,015)
OH 15-17 731 9.3 1.47 (6.8–12.6) || 39,071 (26,859–51,283)
PA 0-4 212 2.5 1.31 (0.9–6.9) || 17,630 (0–35,795)
PA 5-9 261 6.5 1.80 (3.7–11.0) || 42,220 (18,785–65,654)
PA 10-14 416 11.1 2.27 (7.4–16.4) || 69,964 (40,962–98,965)
PA 15-17 284 6.4 1.89 (3.5–11.2) || 26,846 (10,977–42,714)
RI 0-4 195 3.1 1.49 (1.2–7.8) || 1,739 (85–3,393)
RI 5-9 228 8.1 2.54 (4.4–14.7) || 4,525 (1,643–7,407)
RI 10-14 477 7.8 1.70 (5.1–11.9) || 4,244 (2,385–6,104)
RI 15-17 253 7.8 1.90 (4.8–12.4) || 2,764 (1,433–4,095)
TX 0-4 498 4.2 1.37 (2.2–7.9) || 79,943 (28,441–131,445)
TX 5-9 514 6.9 1.50 (4.4–10.5) || 138,019 (78,207–197,832)
TX 10-14 787 8.4 1.78 (5.5–12.6) || 162,830 (92,885–232,775)
TX 15-17 456 5.6 1.46 (3.4–9.3) || 70,979 (34,796–107,162)
UT 0-4 648 1.7 0.58 (0.9–3.3) || 4,313 (1,407–7,220)
UT 5-9 645 5.7 1.09 (3.9–8.3) || 14,718 (9,064–20,372)
UT 10-14 1,192 7.6 0.95 (5.9–9.7) || 19,230 (14,435–24,025)
UT 15-17 767 8.0 1.12 (6.0–10.5) || 12,027 (8,647–15,407)
VT 0-4 213 (.–.) || 684 (.–.)
VT 5-9 327 4.4 1.27 (2.4–7.7) || 1,308 (563–2,054)
VT 10-14 421 5.1 1.32 (3.1–8.4) || 1,612 (791–2,433)
VT 15-17 330 6.3 1.48 (3.9–9.9) || 1,328 (726–1,930)
WI 0-4 211 (.–.) || 1,490 (.–.)
WI 5-9 215 11.5 4.06 (5.6–22.1) || 38,655 (9,701–67,608)
WI 10-14 348 6.8 2.10 (3.7–12.3) || 24,008 (9,081–38,934)
WI 15-17 259 5.9 1.50 (3.6–9.6) || 12,755 (6,675–18,834)
Territory
PR 0-4 185 6.5 2.13 (3.4–12.1) || 11,094 (3,697–18,492)
PR 5-9 242 12.0 2.48 (7.9–17.7) || 21,677 (12,342–31,013)
PR 10-14 276 11.2 2.16 (7.6–16.2) || 21,660 (13,144–30,176)
PR 15-17 186 12.0 2.95 (7.3–19.1) || 15,706 (7,920–23,491)
VI 0-4 49 (.–.) || 0 (.–.)
VI 5-9 91 16.8 7.63 (6.5–37.0) || 1,103 (10–2,197)
VI 10-14 59 16.0 8.40 (5.3–39.3) || 1,194 (0–2,560)
VI 15-17 40 (.–.) || 254 (.–.)

For additional information on methods and variable description, refer to “Technical Information, available at: https://www.cdc.gov/asthma/brfss/2021/child/brfsschildtechinfo.html
aAged 0-17 years
bCurrent asthma question: Does the child still have asthma?
cWeighted number of respondents who answered the current asthma question
dUnweighted number of respondents who answered the current asthma question
eCI denotes confidence interval
fTotal includes data from 29 states and DC, but excludes Puerto Rico and U.S. Virgin Islands
(.–.) or empty cell: Suppressed if the normal approximation to the binomial distribution does not apply due to small sample size or relative standard error (RSE) > 30%

Asthma and Community Health Branch, National Center for Environmental Health
Centers for Disease Control and Prevention

View Page In: PDF - 226 KB